Drug
Tucatinib clinical trials
Also written Tukysa, ONT-380, ARRY-380 and Irbinitinib.
- studies test it
- 51
- open now
- 16
- in phase 3
- 5
- first study started
- 2008
Keep track of what changes. Save the tucatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2023 (12)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 8 |
| 2023 | 12 |
| 2024 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 19
- Phase 2
- 32
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 30
Seagen Inc. (9) · Seagen, a wholly owned subsidiary of Pfizer (5) · Pfizer (3) · Dana-Farber Cancer Institute (3) · Criterium, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · UNICANCER (2) · M.D. Anderson Cancer Center (2)
Often tested with
Tested in the same studies.
Trastuzumab (23) · Pertuzumab (7) · Ado-Trastuzumab Emtansine (6) · Capecitabine (5) · Trastuzumab deruxtecan (5) · Paclitaxel (3) · Trifluridine tipiracil drug combination (3) · Olaparib (3)
Studies
Open first, then newest update. How each study uses tucatinib is read from its arms, and is right about nine times in ten.
Testing it · 51
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Tucatinib
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Written as Tucatinib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Tucatinib Continuation StudyNot yet recruitingPhase 4PfizerNCT07768358Written as tucatinib
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Written as Tucatinib
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651Written as tucatinib
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05673928Written as Tucatinib
- A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05672524Written as Tucatinib
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Tucatinib plus trastuzumab and pertuzumab
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Tucatinib
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingPhase 2SCRI Development Innovations, LLCNCT05748834Written as Tucatinib
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingPhase 2Sunnybrook Health Sciences CentreNCT06016387Written as Tucatinib 150 MG
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingPhase 2Institut CurieNCT07193394Written as Tucatinib (ONT-380)
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingPhase 2UNICANCERNCT05800275Written as Tucatinib Oral Tablet
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingPhase 1The Netherlands Cancer InstituteNCT06162559Written as Tucatinib
- Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingPhase 1Jonathan RiessNCT06067776Written as Tucatinib
- Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedPhase 2Breast Cancer Trials, Australia and New ZealandNCT04789096Written as Tucatinib
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05132582Written as Tucatinib
- A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingPhase 2PfizerNCT04721977Written as Tucatinib
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04579380Written as tucatinib
See all 51 studies that test tucatinib →
Given in every arm · 10 — tucatinib is usual care beside what is tested
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Written as Tucatinib
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNot yet recruitingPhase 1/2MedSIRNCT07494448Written as Tucatinib
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT06157892Written as tucatinib
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingPhase 1OnKure, Inc.NCT06239467Written as Tucatinib
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04430738Written as tucatinib
- A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT04538742Written as Tucatinib
- Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersCompletedPhase 1Jazz PharmaceuticalsNCT02892123Written as Tucatinib
- Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerCompletedPhase 2Seagen Inc.NCT03043313Written as Tucatinib
- A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersTerminatedPhase 1/2Silverback TherapeuticsNCT05091528Written as tucatinib
- A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerCompletedPhase 1Seagen Inc.NCT02025192Written as Tucatinib
As the comparator · 1 — what is tested is compared with tucatinib
Codes
What other systems call tucatinib · ClinicalTrials.gg INT001276
- MeSH (NLM) C000705452tucatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 234248D0HHTUCATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2361285One source FDA
- Wikidata Q25100690tucatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77896TucatinibOne source FDA
- DrugBank DB11652One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705452 | tucatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 234248D0HH | TUCATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2361285 | — | One source FDA |
| Wikidata | Q25100690 | tucatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77896 | Tucatinib | One source FDA |
| DrugBank | DB11652 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.